```json
{
"content": [
{
"type": "paragraph",
"content": "Mucormycosis, a rare but severe fungal infection, poses significant challenges in immunocompromised populations. The Mucormycosis market size is driven by rising incidence of diabetes, cancer, and post-transplant immunosuppression, alongside advancements in antifungal therapies. This market overview provides a growth outlook and market forecast for 2021–2033, emphasizing industry expansion through innovations in diagnostics and treatment. The global market, valued at approximately $850 million in 2025, is projected to grow at a CAGR of 6.8% through 2033."
},
{
"type": "chart",
"chartType": "segment-stacked",
"data": {
"segments": ["Antifungal Drugs", "Diagnostic Tools", "Supportive Therapies"],
"periods": ["2021", "2022", "2023", "2024", "2025", "2026", "2027", "2028", "2029", "2030", "2031", "2032", "2033"],
"values": [
[45, 50, 55, 60, 65, 70, 75, 78, 82, 85, 88, 90, 92], // Antifungal Drugs
[15, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38], // Diagnostic Tools
[10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22] // Supportive Therapies
]
}
},
{
"type": "paragraph",
"content": "Key drivers include technological advancements in rapid diagnostics and regulatory incentives for antifungal R&D. North America dominates the market due to high healthcare expenditure and prevalence of risk factors, while Asia-Pacific is the fastest-growing region, fueled by rising diabetes prevalence and improving healthcare infrastructure. Strategic collaborations among biopharma firms and increasing awareness around early diagnosis are pivotal for industry expansion, ensuring the Mucormycosis market forecast remains robust amid evolving treatment paradigms."
}
]
}
```
